The winners of the hackathon included a contact tracing tool for schools, a soap dispenser to promote handwashing, a virus-killing filter, and more. Photo via Rice University Public Relations

As fall creeps closer, the need for a safe way to reopen schools becomes more and more dire. A team of Rice University students created a software that might help on that front.

SchoolTrace, a software that uses the schedules of students and faculty for COVID-19 contact tracing in schools, won top honors in the 2020 Rice Design-A-Thon, which took place July 17 to 19 online this year due to the pandemic. The hackathon was planned to be held in person during the fall semester, but organizers moved up the date to focus on coronavirus solutions. Twenty-three teams — comprised of 116 undergraduate competitors — participated.

"We wanted to provide students with a meaningful summer opportunity and the potential for a significant public health impact," says Carrigan Hudgins, a Sid Richardson College senior and co-coordinator, in a news release. "At one point, we considered cancelling, but hosting it virtually instead actually allowed us to reach a broader base of students across Texas and out of state."

SchoolTrace and its contact tracing tech that doesn't raise privacy concerns with tracking sensors or mobile phone apps took the $1,000 first price. Justin Cheung, Nick Glaze, Mit Mehta, Tyler Montague and Huzaifah Shamim — all juniors majoring in electrical and computer engineering — also received $500 for excelling in the digital age of health care track.

The teams that came in second and third place received $800 and $600, respectively, and the winners of each of the three design tracks also scored $500. The prizes were sponsored by Rice's George R. Brown School of Engineering, Rice's student chapter of the Biomedical Engineering Society and the Southwest National Pediatric Device Innovation Consortium.

Aside from the cash prizes, the students also received valuable guidances and feedback from industry experts.

"Having the judges and our team vouch for the actual solution, when we can propose it to different competitions and incubators around Texas and the country, is more important than the cash prizes," says co-coordinator Franklin Briones, a Brown College senior who competed in previous design-a-thons at Rice. Briones and Hudgins co-coordinated this year's event with Wiess College senior Eric Torres.

Here were the other award-winning innovations to come out of the program:

  • Second place and pediatric track winner — "Team SARS Wars: A New Hope." The team created a soap dispenser attachment that plays music and rewards children with stickers if they wash their hands for 20 seconds. Team members included: Anyssa Castorina, Aman Eujayl, Diego Lopez-Bernal, Janet Lu, Rubén Sebastián Marroquín, and Belén Szentes, all sophomores from Rice.
  • Third place — "The (d^3x/dt^3)(s)." COV-COM is a wall-mounted filtration system that catches and kills COVID-19 created by a team of juniors and seniors from the University of Texas at San Antonio. Team members included: Olivia Garza, Juan Herrera, Frida Montoya, Aishwarya Sathish, Samantha Strahan, and Morgan Struthers.
  • Global health track winner — "The Duncaroo Designers." The team from Rice created affordable desk partitions that could be used in schools with limited funds. Team members included: senior Rachel Bui and sophomores Jacob Duplantis, Charlie Gorton, Andrei Mitrofan, Anh Nguyen, and Vivian Wong.

Each of the teams were tasked Friday (July 17) evening with the prompt to "design and present a solution (either a product or a method) to address the treatment, prevention or non-medical related needs of the COVID-19 pandemic." Final presentations took place final presentations Sunday afternoon.

"The needs-finding for those problems was the most cumbersome part," Briones says in the release. "Not because it's hard to find problems, but because COVID-19 is so continually changing. It was hard to find which problem was the most important one."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.